1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 44,400 | 44,800 | 08.04. | |
| 44,000 | 45,200 | 08.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 2 | GlobeNewswire (USA) | ||
| 18.03. | Stifel raises Spyre stock price target to $92 on TL1A potential | 1 | Investing.com | ||
| 16.03. | Leerink reiterates Spyre stock Outperform on faster trial timeline | 2 | Investing.com | ||
| 16.03. | Guggenheim: Spyre Therapeutics bleibt Top-Pick für 2026 | 3 | Investing.com Deutsch | ||
| 16.03. | Spyre Therapeutics stock remains top 2026 pick at Guggenheim | 1 | Investing.com | ||
| 06.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 19.02. | Earnings Summary: Spyre Therapeutics Q4 | 2 | Benzinga.com | ||
| 19.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 205 | GlobeNewswire (Europe) | On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second... ► Artikel lesen | |
| 19.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.02. | Spyre Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 16.02. | Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 | 3 | Insider Monkey | ||
| 06.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| 06.02. | Spyre Therapeutics appoints Kate Tansey Chevlen as Chief Commercial Officer | 2 | PMLiVE | ||
| 23.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 15.01. | Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating | 3 | Insider Monkey | ||
| 12.01. | Spyre Therapeutics accelerates clinical trial timeline for IBD treatments | 2 | Investing.com | ||
| 12.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 | 232 | GlobeNewswire (Europe) | "6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete... ► Artikel lesen | |
| 12.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 54,00 | +2,86 % | Guggenheim raises Oruka Therapeutics price target on trial outlook | ||
| PALVELLA THERAPEUTICS | 103,00 | 0,00 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales | Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S.... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 75,50 | +1,34 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| LENZ THERAPEUTICS | 9,445 | -2,93 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen | |
| QIAGEN | 35,435 | +3,34 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,810 | 0,00 % | Stifel initiates Summit Therapeutics stock with buy rating | ||
| IMMUNOVANT | 24,730 | +0,45 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| EVOTEC | 4,676 | +4,61 % | EQS-News: Evotec SE: Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer
01.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 79,05 | +2,20 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| ARCELLX | 114,79 | -0,01 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| VERA THERAPEUTICS | 40,360 | +0,75 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,515 | +7,60 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| ADMA BIOLOGICS | 9,820 | +5,93 % | Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026? | ||
| COGENT BIOSCIENCES | 36,950 | +3,76 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| ERASCA | 16,940 | -0,70 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,600 (-3,62 %) liegt der Kurs bei 42,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.